Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors (Q36712986)

15 August 2017

1 reference

title

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors (English)

1 reference

15 August 2017

3

1 reference

PubMed ID

17237841

15 August 2017

Jean-Charles Fruchart

series ordinal

2

object named as

Jean-Charles Fruchart

0 references

Philippe Gervois

series ordinal

1

object named as

Philippe Gervois

1 reference

15 August 2017

1 February 2007

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

1 reference

15 August 2017

3

1 reference

15 August 2017

145-156

1 reference

15 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpendmet0397

15 August 2017

0 references

cites work

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Regulation of lipid and lipoprotein metabolism by PPAR activators

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Therapeutic roles of peroxisome proliferator-activated receptor agonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

PPAR gamma is required for placental, cardiac, and adipose tissue development

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Obesity is associated with macrophage accumulation in adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Activation of PPARdelta alters lipid metabolism in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

PPARs in atherosclerosis: the clot thickens

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome proliferator-activated receptors and cardiovascular remodeling

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0397

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0397

1 reference

PubMed ID

17237841

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

17237841